Last reviewed · How we verify
A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
Details
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 38 |
| Start date | 2023-11-01 |
| Completion | 2026-07 |
Conditions
- Pleural Mesothelioma
Interventions
- Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin
Primary outcomes
- Objective Response Rate (ORR) — Up to 36 months
defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
Countries
China